The COVID-19 pandemic permanently reshaped healthcare delivery, forcing a rapid transition to virtual care that has fundamentally altered how chronic diseases like diabetes are managed. For the roughly 37.3 million Americans living with diabetes, as documented by the CDC, this shift was particularly significant, transforming how continuous glucose monitors (CGM), insulin pumps, and clinical expertise intersect with daily life. As the public health emergency fades into a historical footnote, the healthcare system faces a complex challenge: refining these temporary measures into a permanent, equitable, and highly effective framework for diabetes care. This transition moves beyond simple video visits to a truly integrated model that leverages connected devices, artificial intelligence, and patient-centered design to improve outcomes and reduce burden.

The Evolution of Remote Monitoring and Data Integration

Remote monitoring has rapidly evolved from a niche capability into a cornerstone of modern diabetes management. The ability to track glucose levels, insulin delivery, and physiology in near real-time allows clinicians and patients to make proactive, data-driven adjustments that were impossible with traditional fingerstick logs. This shift is driving a transformation in how care is delivered and measured.

Continuous Glucose Monitoring as a Standard of Care

Devices such as the Dexcom G7 and Abbott FreeStyle Libre 3 have moved CGMs from a reactive tool to a proactive system. These sensors transmit glucose data directly to smartphones and cloud-based platforms, enabling healthcare providers to access critical information between visits. This data stream allows for proactive adjustments to insulin doses, meal timing, and physical activity. The integration of CGM data with insulin pumps—often called sensor-augmented pump therapy—creates a powerful closed-loop system. Hybrid closed-loop systems, such as the Medtronic MiniMed 780G and the Tandem t:slim X2 with Control-IQ, automate much of the burden of insulin delivery, significantly improving Time-in-Range (TIR) and reducing hypoglycemia risk. Telehealth facilitates the remote onboarding and troubleshooting of these complex devices, ensuring patients receive timely support without requiring travel to a specialty clinic.

The Shift from HbA1c to Time-in-Range

One of the most profound changes enabled by the convergence of CGMs and telehealth is the shift from HbA1c as the primary metric to Time-in-Range. While HbA1c provides an average over months, it can mask dangerous swings in glucose levels. TIR, typically measured between 70 and 180 mg/dL, offers a dynamic view of daily glucose control. Telehealth platforms that display TIR data visually allow clinicians and patients to identify patterns immediately—such as post-meal spikes or overnight lows—and adjust therapy accordingly. This nuanced data fosters more collaborative and personalized care plans during virtual visits.

Interoperability and the Future of Connected Devices

The true potential of remote monitoring hinges on interoperability. Data must flow seamlessly between CGMs, insulin pumps, smart pens, activity trackers, and electronic health records. Standards like HL7 FHIR are increasingly adopted to enable this integration. When devices communicate effectively, a clinician can see a patient's glucose trends alongside their step count and carbohydrate intake during a single telehealth session. However, data silos remain a significant barrier. Device manufacturers and health systems must prioritize open Application Programming Interfaces (APIs) to avoid locking patients and providers into proprietary ecosystems. The American Diabetes Association advocates for these open standards to ensure that all people with diabetes can benefit from connected care, regardless of the devices they choose.

Artificial Intelligence and Predictive Analytics in Routine Care

Artificial intelligence is moving beyond the hype cycle into practical, clinical applications for diabetes. Machine learning algorithms, trained on vast datasets of CGM readings, insulin doses, and lifestyle factors, can predict hypoglycemic events hours in advance. This capability shifts diabetes management from reactive problem-solving to proactive prevention.

Machine Learning for Hypoglycemia Prevention

Systems like the DreaMed Diabetes Advisor and algorithms embedded within platforms like Glooko and Tidepool aggregate data from multiple devices to generate actionable insights. For instance, an algorithm might detect a pattern of overnight hypoglycemia linked to a specific basal rate or meal composition and alert the patient and provider before a severe event occurs. The FDA has cleared several AI-powered applications for insulin dose adjustments, signaling a regulatory path that encourages innovation while maintaining rigorous safety standards. These tools not only help clinicians personalize complex treatment regimens but also empower patients to understand their glucose trends and take corrective action autonomously.

Managing Algorithmic Bias and Ensuring Equity

As AI assumes a greater role in treatment decisions, addressing algorithmic bias is essential. If training data does not adequately represent diverse populations—including different races, ethnicities, and socioeconomic backgrounds—the resulting algorithms may be less accurate for those groups. This could widen existing disparities in diabetes outcomes. Manufacturers and health systems must validate their algorithms across diverse cohorts and ensure that telehealth platforms provide equitable access to advanced decision-support tools for all patients.

The Expansion of Virtual Multidisciplinary Care Teams

Diabetes is a complex, multi-system disease that benefits from a team-based approach. Telehealth has enabled the creation of virtual multidisciplinary clinics where patients can see an endocrinologist, diabetes educator, dietitian, and mental health professional in a single coordinated session. This model removes logistical barriers and fosters comprehensive care.

Integrating Behavioral Health and Diabetes Education

Diabetes distress, depression, and anxiety are common comorbidities that significantly impact self-management and outcomes. Virtual visits make it easier for patients to access integrated behavioral health support without the stigma or inconvenience of a separate appointment. A patient struggling with burnout can have a brief session with a psychologist immediately following an insulin pump adjustment with their endocrinologist. Certified Diabetes Care and Education Specialists (CDCES) play a pivotal role in these virtual teams, providing ongoing education on carbohydrate counting, insulin dose adjustments, and technology troubleshooting. Telehealth allows for more frequent, shorter check-ins with educators, which is often more effective than brief in-person appointments.

Remote Retinal Screening and Preventative Care

Diabetic retinopathy is a leading cause of blindness, but early detection and treatment can prevent vision loss. Smartphone-based retinal cameras, combined with AI interpretation, now enable effective screening during virtual visits. Patients can have their retinas photographed at a local pharmacy, primary care office, or even at home using an adapter, with the images reviewed remotely by an ophthalmologist. This expands access to preventive eye care, particularly in underserved rural and urban communities where access to specialists is limited. The convenience of virtual visits also improves attendance rates for routine preventative care, which is critical for managing the long-term complications of diabetes.

Persistent Barriers to Equitable Telehealth Access

Despite the tremendous promise of virtual diabetes care, significant obstacles prevent its benefits from being universally accessible. Addressing these barriers is critical to ensuring that technology does not worsen existing health disparities.

The Digital Divide and Health Literacy

The advantages of CGMs, smart pumps, and telehealth platforms are not evenly distributed. Patients in rural areas, those with lower incomes, and older adults often lack reliable broadband internet or compatible smart devices. According to the Federal Communications Commission, approximately 14.5 million Americans still lack access to fixed broadband at threshold speeds. For diabetes care, this translates into delayed CGM data transmission, interrupted video consultations, and difficulty using cloud-based management tools. Beyond connectivity, digital literacy poses a significant hurdle. A patient who is uncomfortable navigating a smartphone app will struggle to share CGM data or participate in a video visit. Healthcare systems must invest in digital health navigators and community-based training programs that provide step-by-step support. Partnerships with local libraries, senior centers, and faith-based organizations can establish telehealth kiosks where patients access virtual care in a private, supported environment.

Data Privacy and Cybersecurity Risks

The proliferation of connected diabetes devices generates a vast amount of sensitive health data. While this data stream enables highly personalized care, it also creates attractive targets for cybercriminals. High-profile breaches in the health technology sector have eroded patient trust. For diabetes patients, the threats are uniquely personal: theoretical risks include remote alteration of insulin pump settings or unauthorized access to CGM data, which could lead to discrimination by insurers or employers. Compliance with the Health Insurance Portability and Accountability Act (HIPAA) is mandatory, but many wellness-focused diabetes apps operate outside HIPAA's direct scope. The FDA has issued cybersecurity guidance for medical devices, recommending that manufacturers implement robust security testing and reporting mechanisms. Healthcare providers must carefully vet telehealth platforms and device vendors, prioritize end-to-end encryption, and educate patients on best practices such as using strong passwords and enabling two-factor authentication.

Reimbursement Uncertainty and Licensing Hurdles

The financial sustainability of telehealth programs depends on stable reimbursement policies. During the pandemic, Medicare and many private insurers temporarily waived geographic restrictions and expanded covered services. These flexibilities are now expiring or being revised. The Centers for Medicare & Medicaid Services (CMS) has extended many telehealth provisions through 2025, but the long-term future remains uncertain. Specific remote patient monitoring (RPM) codes (99453, 99454, 99457, 99458) provide a pathway for reimbursing the time providers spend reviewing CGM data and communicating with patients. However, these codes often require specific consent and time-tracking processes that can be administratively burdensome. Additionally, state licensing laws that limit cross-border telemedicine create barriers for patients living near state borders. The Interstate Medical Licensure Compact has streamlined multi-state licensing, but not all states participate. Advocacy groups are pushing for permanent regulatory changes that treat telehealth as a standard care modality, ensuring that patients have continuity of access to their specialist providers.

Shaping a Sustainable and Equitable Future

To realize the full potential of telehealth in diabetes care, stakeholders across healthcare, technology, and policy must collaborate to build a system that is accessible, secure, and evidence-based. This requires focused action on infrastructure, security standards, and policy alignment.

Strengthening Infrastructure and Digital Literacy

Closing the digital divide requires a sustained investment in broadband infrastructure, particularly in rural, tribal, and low-income urban communities. Federal programs like the Affordable Connectivity Program should be expanded and made permanent to ensure that cost is not a barrier to connectivity. Healthcare organizations should establish device loan programs for CGMs, insulin pumps, and tablets. Health systems should invest in remote patient monitoring platforms designed to function effectively on low-bandwidth connections, using asynchronous data transmission when real-time video is not possible. Complementing infrastructure with robust digital literacy training is equally important. Peer support groups and community health workers can act as trusted guides, helping patients learn to use their devices and interpret their data.

Enhancing Security and Interoperability Standards

As diabetes devices become more interconnected, cybersecurity must be treated as a patient safety imperative. The FDA should continue to update its premarket and postmarket cybersecurity guidance, requiring manufacturers to demonstrate robust security testing throughout the product lifecycle. Healthcare providers should adopt zero-trust architectures for their telehealth platforms and mandate routine security audits. Industry-wide standards for data interoperability, such as HL7 FHIR, are critical for reducing fragmentation and enabling secure data exchange between devices, electronic health records, and telehealth platforms. Patients should be given clear, plain-language resources to understand the risks and protections associated with their connected devices. A secure ecosystem builds the trust necessary for widespread adoption.

Solidifying Telehealth Policy and Advancing Value-Based Care

Policymakers should enact permanent telehealth expansions that cover the full spectrum of diabetes services, including CGM data review, remote insulin pump adjustments, and multidisciplinary team visits. Reimbursement rates for telehealth should maintain parity with in-person care to prevent financial disincentives for providers. The Interstate Medical Licensure Compact should be adopted by all states to facilitate cross-border specialist access. Furthermore, the shift toward value-based payment models rewards outcomes such as Time-in-Range and reduced hospitalizations, rather than simply the volume of visits. Medicare Advantage plans and Accountable Care Organizations should be encouraged to include comprehensive remote diabetes management programs as a core benefit. By aligning financial incentives with patient outcomes, policymakers can accelerate the adoption of effective telehealth models.

Telehealth has already proven its value in diabetes management by improving convenience, enabling data-driven decisions, and maintaining continuity of care during a global crisis. The path forward is not without challenges, but with deliberate, coordinated action to improve access, strengthen security, and align regulatory frameworks, telehealth can become a cornerstone of high-quality, patient-centered diabetes care. By learning from the rapid innovations of the pandemic and building on the momentum of connected health technology, the healthcare community can shape a future where every person with diabetes has the tools, support, and clinical partnership they need to thrive, regardless of their location or circumstances.